SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin rises on inking BTA to carve out two API manufacturing sites

18 Oct 2023 Evaluate

Lupin is currently trading at Rs. 1200.45, up by 3.00 points or 0.25% from its previous closing of Rs. 1197.45 on the BSE.

The scrip opened at Rs. 1190.05 and has touched a high and low of Rs. 1203.50 and Rs. 1190.05 respectively. So far 7458 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1215.20 on 17-Oct-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1215.20 and Rs. 1160.05 respectively. The current market cap of the company is Rs. 54455.93 crore.

The promoters holding in the company stood at 47.06%, while Institutions and Non-Institutions held 44.42% and 8.52% respectively.

Lupin has entered into a Business Transfer Agreement (BTA) with Lupin Manufacturing Solutions (LMSL), wholly owned subsidiary of the Company, to carve out two Active Pharmaceutical Ingredients (API) manufacturing sites situated at Dabhasa and Visakhapatnam and select R&D operations, including fermentation, at Lupin Research Park, Pune. Earlier, the company had received approval from board of directors to enter into a business transfer agreement.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2398.70 2.20 (0.09%)
02-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.55
Dr. Reddys Labs. 1346.25
Cipla 1456.25
Zydus Lifesciences 1099.65
Lupin 2398.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: